Clinical trials
Severe Infection clinical trials
Below are recruiting severe infection clinical trials, each written for real people, not researchers. We’re tracking 62 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07052409Enrolling by invitation
Protecting HIV-exposed infants from severe infections
This trial studies ways to protect babies who were exposed to HIV before birth but are not infected themselves. It aims to find better interventions to prevent severe infections in these infants.
JohannesburgAges 6 months–45 years - NCT07094048RecruitingPhase 4
Immunoglobulins for multiple myeloma patients on BCMA T-cell engagers
This trial tests whether giving immunoglobulins (a treatment to boost your immune system) helps multiple myeloma patients who are receiving a BCMA-directed T-cell engager therapy. It aims to see if this can reduce infections and improve outcomes.
Lévis, QuebecAges 18 years+ - NCT04961580Recruiting
Study of ceftazidime dosing in sick children
This trial measures how ceftazidime (an antibiotic) moves through the body and how it works in children with severe infections in the pediatric intensive care unit. It may help doctors choose safer, more effective dosing for kids.
Shanghai, Shanghai MunicipalityAges 3 months–18 years - NCT05565222RecruitingPhase 3
Testing two antibiotics as alternatives for ICU severe ESBL infections
This study compares two antibiotics—piperacillin-tazobactam or temocillin—to treat severe ICU infections caused by certain hard-to-treat gut bacteria (ESBL). It may help patients avoid the use of carbapenem antibiotics like meropenem when the bacteria are susceptible.
ParisAges 18 years+ - NCT06102070Recruiting
Genetic study of severe infections
This study looks for genetic reasons why some people get very serious infections. If you or a family member has had a rare, severe infection, researchers will analyze your DNA to find genes that might make you more vulnerable.
Paris, Île-de-France RegionAges Any age - NCT06161870RecruitingPhase 4
Individualized vancomycin dosing for NICU patients
This study tests a personalized dosing approach for the antibiotic vancomycin given to patients in the neurological ICU. It aims to find the right dose for each patient to improve treatment and reduce side effects.
Changsha, HunanAges 18 years+ - NCT06372444Recruiting
Kidney injury in severe infections study
This study looks at how severe infections like sepsis can hurt the kidneys. By using special scans (PET-CT), researchers hope to better understand why this happens, which could lead to better treatments.
UppsalaAges 30 years+ - NCT07609576Recruiting
Tracking Infections in Blood Cancer Patients on Bispecific Antibody Treatment
This study follows adults with blood cancers (like multiple myeloma or lymphoma) who are starting a newer type of immunotherapy called bispecific antibodies. Researchers want to understand what infections might develop during this treatment and how often they occur, which could help doctors better protect patients.
Madrid, MadridAges 18 years+ - NCT06197152Recruiting
RSV severity markers in hospitalized adults
This study looks for markers in the blood that can tell how serious an RSV infection might become. If you are hospitalized with RSV and have breathing symptoms, this trial will follow your recovery and test for clues about your illness.
CréteilAges 18 years+ - NCT04712539RecruitingPhase 2
Baloxavir and oseltamivir for severe flu in immune-compromised people
This trial tests whether two flu medicines—baloxavir and oseltamivir—work better to treat influenza in people with weakened immune systems (like transplant or blood cancer patients). It may help reduce severe complications, especially when flu affects the lungs or is at high risk to do so.
Houston, TexasAges 12 years+ - NCT06618989Recruiting
Predicting serious bacterial infection in febrile infants
This trial is testing a new blood test to help doctors tell which babies under three months with fever are at risk for a serious bacterial infection. If successful, it could help avoid unnecessary antibiotics and hospital stays.
Paris, FranceAges 1 week–3 months - NCT01011712Recruiting
Study immune causes of severe viral infections
This study looks at why some people have severe or unusual viral infections, even when they do not have a known immune problem. It collects blood and tissue samples to better understand possible inherited immune issues and may help future diagnosis and treatment.
Bethesda, MarylandAges 2–100 - NCT07130799Recruiting
Monitoring immune response in severe abdominal infections with fungal risk
This trial monitors a marker of immune function (monocyte HLA-DR) in patients with severe abdominal infections that may lead to fungal infections. It aims to see if this marker can help guide treatment.
Vandœuvre-lès-NancyAges 18 years+ - NCT07004049RecruitingPhase 4
Testing combinations for resistant Gram-negative infections
This study tests different antibiotic combinations for severe infections caused by hard-to-treat Gram-negative bacteria (like Pseudomonas or Acinetobacter). The goal is to find the best treatment for bloodstream infections or pneumonia that started in the hospital.
Brisbane, QueenslandAges 18 years+ - NCT04326426Enrolling by invitationPhase 3
Study of tradipitant for severe or critical COVID-19
This trial tests whether tradipitant can improve outcomes for adults with severe or critical COVID-19, including pneumonia and low oxygen. It may help patients whose lungs are significantly affected and who need careful hospital-level care.
New York, New YorkAges 18–90 - NCT06434701Recruiting
Severe COVID-19 in children in emergency rooms
This trial is studying children who are very sick from COVID-19 or have a related condition called MIS-C. It aims to understand how severe COVID-19 affects children and improve care.
AfulaAges birth–16 years - NCT07063095RecruitingPhase 3
Testing two antibiotics combined for serious bacterial infections
This study tests whether combining two antibiotics (ceftazidime and fosfomycin) works better than ceftazidime alone for hospitalized adults with serious bacterial infections. If you have a severe infection thought to be caused by Gram-negative bacteria, this trial may offer a new treatment option.
Geneva, Canton of GenevaAges 18 years+ - NCT07013474RecruitingPhase 3
Study of ibuzatrelvir for immunocompromised adults with COVID-19
This trial tests an investigational medicine called ibuzatrelvir for adults with COVID-19 who have a weakened immune system. The study aims to see if it helps them recover and avoid severe illness.
Canoga Park, CaliforniaAges 18 years+ - NCT07484607Recruiting
Study on infections and treatments in cystic fibrosis exacerbations
This study looks at how lung infections and inflammation affect people with cystic fibrosis during severe flare-ups. It aims to understand which antibiotics work best and why, so your care team can choose the right treatment for you.
CardiffAges 16 years+ - NCT07358910Recruiting
Tracking infectious diseases in communities
This study looks at how infections spread in villages in Cambodia. If you live in a participating village, you might help us understand and prevent disease outbreaks.
Phnom Penh, Phnom PenhAges 2–75 - NCT07214571RecruitingPhase 2
Study of S-337395 for RSV in high-risk adults
This trial tests an experimental drug called S-337395 for adults with RSV who are not in the hospital but are at high risk for severe illness. It aims to see if the drug can help prevent symptoms from getting worse.
Los Angeles, CaliforniaAges 18 years+ - NCT05689034RecruitingPhase 2/Phase 3
Azvudine for early COVID-19 in higher-risk adults
This trial studies azvudine in adults with early COVID-19 symptoms to see if it can prevent the illness from getting severe. You may qualify if you’re within about 5 days of symptom start and have risk factors for worsening disease.
Beijing, Beijing MunicipalityAges 18–120 - NCT01068990Recruiting
Testing how to identify pneumonia germs in ICU patients
This study looks at how well doctors can detect and identify the cause of new pneumonia in people in the medical intensive care unit (ICU). It may help improve how pneumonia is diagnosed and treated in critically ill patients.
SeoulAges 16 years+ - NCT06286007Recruiting
How whooping cough and RSV affect asthma in adults
This study looks at how infections like whooping cough and RSV impact asthma symptoms and control in adults. It aims to understand if these infections make asthma worse, which could help improve future treatment and prevention.
Santiago de Compostela, A CoruñaAges 18–99
Hear when a new Severe Infection trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for severe infection?
- Yes. Clin2 currently lists 62 recruiting severe infection studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a severe infection trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a severe infection trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.